Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
Transcript
Are there any novel therapies currently being researched by your division for gynecologic malignancies?
Our division at Stanford in gynecologic oncology is very interested in pushing and investigating very innovative therapies. We have a particular focus on immunotherapies. Immunotherapies can be very diverse. Immune checkpoint inhibitors, as they have been approved, are still being investigated in clinical trials, in particular, in combination with chemotherapy or other immunostimulant drugs.
I’m very excited about cell therapies that allow us to use the body’s own white blood cells, or the patient’s own white blood cells, to potentially create antitumor effects. So, these white blood cells they’re taking out of the patients, they’re potentially genetically modified, so they recognize the tumor. They are then being reinfused, and hopefully recognize the tumor and have antitumor effects.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More